Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada

BACKGROUND: Hereditary angioedema (HAE) is a rare autosomal dominant disease resulting in recurring episodes of swelling, leading to considerable patient morbidity and mortality. Lanadelumab is a plasma kallikrein inhibitor that is approved as 1st line therapy in Canada for long term prophylaxis of...

Descripción completa

Detalles Bibliográficos
Autores principales: Iaboni, Aled, Kanani, Amin, Lacuesta, Gina, Song, Christine, Kan, Manstein, Betschel, Stephen D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306280/
https://www.ncbi.nlm.nih.gov/pubmed/34301329
http://dx.doi.org/10.1186/s13223-021-00579-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306280/
https://www.ncbi.nlm.nih.gov/pubmed/34301329
http://dx.doi.org/10.1186/s13223-021-00579-6

Ejemplares similares